DK2797615T3 - Fremgangsmåde til behandling af melanocortin-4-receptor-associerede forstyrrelser hos heterozygotiske bærere - Google Patents

Fremgangsmåde til behandling af melanocortin-4-receptor-associerede forstyrrelser hos heterozygotiske bærere Download PDF

Info

Publication number
DK2797615T3
DK2797615T3 DK12863862.4T DK12863862T DK2797615T3 DK 2797615 T3 DK2797615 T3 DK 2797615T3 DK 12863862 T DK12863862 T DK 12863862T DK 2797615 T3 DK2797615 T3 DK 2797615T3
Authority
DK
Denmark
Prior art keywords
receptor
associated disorders
heterozygous carriers
treating melanocortin
melanocortin
Prior art date
Application number
DK12863862.4T
Other languages
English (en)
Inventor
Louis A Tartaglia
Bart Henderson
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2797615T3 publication Critical patent/DK2797615T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DK12863862.4T 2011-12-29 2012-12-28 Fremgangsmåde til behandling af melanocortin-4-receptor-associerede forstyrrelser hos heterozygotiske bærere DK2797615T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161581391P 2011-12-29 2011-12-29
PCT/US2012/072026 WO2013102047A1 (en) 2011-12-29 2012-12-28 Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

Publications (1)

Publication Number Publication Date
DK2797615T3 true DK2797615T3 (da) 2019-07-01

Family

ID=48698641

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12863862.4T DK2797615T3 (da) 2011-12-29 2012-12-28 Fremgangsmåde til behandling af melanocortin-4-receptor-associerede forstyrrelser hos heterozygotiske bærere
DK19158126.3T DK3539551T3 (da) 2011-12-29 2012-12-28 Fremgangsmåde til behandling af melanocortin-4 receptor-associerede forstyrrelser i heterozygotiske bærere

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19158126.3T DK3539551T3 (da) 2011-12-29 2012-12-28 Fremgangsmåde til behandling af melanocortin-4 receptor-associerede forstyrrelser i heterozygotiske bærere

Country Status (14)

Country Link
US (5) US9845339B2 (da)
EP (3) EP2797615B1 (da)
CA (1) CA2862444A1 (da)
CY (1) CY1124816T1 (da)
DK (2) DK2797615T3 (da)
ES (2) ES2897559T3 (da)
HR (1) HRP20211950T1 (da)
HU (1) HUE056948T2 (da)
LT (1) LT3539551T (da)
PL (1) PL3539551T3 (da)
PT (2) PT3539551T (da)
RS (1) RS62701B1 (da)
SI (1) SI3539551T1 (da)
WO (1) WO2013102047A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3539551T1 (sl) 2011-12-29 2022-02-28 Rhythm Pharmaceuticals, Inc. Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih
AU2016330773A1 (en) * 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
CN112188898A (zh) 2017-11-15 2021-01-05 节奏制药公司 缓释肽配制品
CA3096055A1 (en) * 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
MXPA05013951A (es) 2003-06-19 2006-02-24 Lilly Co Eli Agonsita del receptor de la melanocortina 4 (mc4) y sus usos.
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
US20070021433A1 (en) * 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
KR101232201B1 (ko) 2005-07-08 2013-02-12 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US8058240B2 (en) * 2006-04-18 2011-11-15 University Of Florida Research Foundation, Inc. Biological active ligands of melanocortin receptors
US20100056433A1 (en) 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
JP2010517943A (ja) 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
EP2106405A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
AR066175A1 (es) 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
AU2008325194B2 (en) 2007-11-05 2012-04-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use melanocortins to treat insulin sensitivity
AU2009257631B2 (en) 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
AR072072A1 (es) 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
ES2421920T3 (es) 2008-08-06 2013-09-06 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de MC4
US8563742B2 (en) 2008-08-29 2013-10-22 High Point Pharmaceuticals, Llc Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
EP2370104A1 (en) 2008-11-25 2011-10-05 Novo Nordisk A/S Peptides for treatment of obesity
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
MX2011013117A (es) 2009-06-08 2012-05-23 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina.
IN2012DN01493A (da) * 2009-08-05 2015-06-05 Ipsen Pharma Sas
HUE031856T2 (en) 2009-08-31 2017-08-28 Tensive Controls Inc Stabilized melanocortin ligands
US20120226018A1 (en) 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
US9415012B2 (en) 2011-06-14 2016-08-16 Ipsen Pharma S.A.S. Sustained-release composition containing peptides as active ingredient
SI3539551T1 (sl) 2011-12-29 2022-02-28 Rhythm Pharmaceuticals, Inc. Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
US10196425B2 (en) 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions
AU2014228460B2 (en) 2013-03-15 2018-11-01 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
CN112188898A (zh) 2017-11-15 2021-01-05 节奏制药公司 缓释肽配制品

Also Published As

Publication number Publication date
HUE056948T2 (hu) 2022-04-28
ES2897559T3 (es) 2022-03-01
US20240190914A1 (en) 2024-06-13
US9845339B2 (en) 2017-12-19
EP2797615B1 (en) 2019-04-03
US10167312B2 (en) 2019-01-01
US10954268B2 (en) 2021-03-23
PL3539551T3 (pl) 2022-02-21
LT3539551T (lt) 2022-01-10
WO2013102047A1 (en) 2013-07-04
US20180194803A1 (en) 2018-07-12
SI3539551T1 (sl) 2022-02-28
US20210061852A1 (en) 2021-03-04
EP3539551A1 (en) 2019-09-18
CY1124816T1 (el) 2022-11-25
HRP20211950T1 (hr) 2022-03-18
EP3988108A1 (en) 2022-04-27
EP3539551B1 (en) 2021-10-06
DK3539551T3 (da) 2021-11-01
EP2797615A4 (en) 2016-05-18
CA2862444A1 (en) 2013-07-04
US20200017546A1 (en) 2020-01-16
WO2013102047A8 (en) 2014-02-27
RS62701B1 (sr) 2022-01-31
PT3539551T (pt) 2021-11-04
ES2732077T3 (es) 2019-11-20
US11702448B2 (en) 2023-07-18
EP2797615A1 (en) 2014-11-05
PT2797615T (pt) 2019-07-11
US20140329743A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
DK3211060T3 (da) Fremgangsmåder til behandling af trækul i et pyrolysesystem
EP2696792A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF THE MAGIC / FOOD TUBE REFLUX DISEASE
FR3000374B1 (fr) Lave-vaisselle et procede de commande d'un tel lave-vaisselle
DK2857019T3 (da) Fremgangsmåde til behandling af multipel sklerose
GB2467710B (en) Methods for treating social disorders
DK2787841T3 (da) Beta-lactoglobulin-peptid til behandling komælksproteinallergi
BR112014001851A2 (pt) método
BR112014001237A2 (pt) método
ITTO20110366A1 (it) Gruppo integrato condensatore-accumulatore-sottoraffreddatore per veicoli
BR112014009795A2 (pt) método
CO6900134A2 (es) Tratamiento de mieloma múltiple
EP2672996A4 (en) METHOD AND SYSTEMS FOR TREATING OR PREVENTING PREGNANT BLOOD PRESSURE DRESSING
DK2797615T3 (da) Fremgangsmåde til behandling af melanocortin-4-receptor-associerede forstyrrelser hos heterozygotiske bærere
DK2714729T3 (da) Midler og fremgangsmåder til diagnosticering og behandling af multipel sklerose
EP2773959A4 (en) FRACTIONATION OF PROTEINS ACCORDING TO THEIR ISOELECTRIC POINT
DK3404041T3 (da) Fremgangsmåde til behandling af osteoporose
EP2720692A4 (en) CATHEPSIN INHIBITORS FOR TREATING NEURONAL LOSS IN MICROGLIE MEDIATION IN THE CENTRAL NERVOUS SYSTEM
DE112012000253A5 (de) Vorrichtung zum bördeln von rohrenden
FR2971397B1 (fr) Recifs artificiels notamment pour especes sedentaires
DK2520713T3 (da) Tungeskinne til sporskifte
ITRE20120001A1 (it) Wickelhulse zum haspeln von bandformigen produkte
DE202011102501U8 (de) Vorrichtung zum Reinigen von Dachrinnen
DK2559653T3 (da) Justerbart beslag til ridning
ITTO20110429A1 (it) System und verfahren zum einspeisen von einzuspeisenden mediendaten in einen multiplex